Psoas muscle index is not representative of skeletal muscle index for evaluating cancer sarcopenia.
CT scan
Cancer sarcopenia
L3
Low muscle mass
Psoas
Skeletal muscle index
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
01
02
2023
received:
18
10
2022
accepted:
28
02
2023
medline:
7
8
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
A common method for diagnosing sarcopenia involves estimating the muscle mass by computed tomography (CT) via measurements of the cross-sectional muscle area (CSMA) of all muscles at the third lumbar vertebra (L3) level. Recently, single-muscle measurements of the psoas major muscle at L3 have emerged as a surrogate for sarcopenia detection, but its reliability and accuracy remain to be demonstrated. This prospective cross-sectional study involved 29 healthcare establishments and recruited patients with metastatic cancers. The correlation between skeletal muscle index (SMI = CSMA of all muscles at L3/height Seven hundred and sixty-six patients were analysed (mean age 65.0 ± 11.8 years, 50.1% female). Low SMI prevalence was 69.1%. Correlation between the SMI and PMI for the entire population was 0.69 (n = 731, P < 0.01). PMI cut-offs for sarcopenia were estimated in the development population at <6.6cm A diagnostic test employing single-muscle measurements of the psoas major muscle as a surrogate for sarcopenia detection was evaluated but found to be unreliable. The CSMA of all muscles must be considered for evaluating cancer sarcopenia at L3.
Sections du résumé
BACKGROUND
A common method for diagnosing sarcopenia involves estimating the muscle mass by computed tomography (CT) via measurements of the cross-sectional muscle area (CSMA) of all muscles at the third lumbar vertebra (L3) level. Recently, single-muscle measurements of the psoas major muscle at L3 have emerged as a surrogate for sarcopenia detection, but its reliability and accuracy remain to be demonstrated.
METHODS
This prospective cross-sectional study involved 29 healthcare establishments and recruited patients with metastatic cancers. The correlation between skeletal muscle index (SMI = CSMA of all muscles at L3/height
RESULTS
Seven hundred and sixty-six patients were analysed (mean age 65.0 ± 11.8 years, 50.1% female). Low SMI prevalence was 69.1%. Correlation between the SMI and PMI for the entire population was 0.69 (n = 731, P < 0.01). PMI cut-offs for sarcopenia were estimated in the development population at <6.6cm
CONCLUSIONS
A diagnostic test employing single-muscle measurements of the psoas major muscle as a surrogate for sarcopenia detection was evaluated but found to be unreliable. The CSMA of all muscles must be considered for evaluating cancer sarcopenia at L3.
Identifiants
pubmed: 37203274
doi: 10.1002/jcsm.13230
pmc: PMC10401530
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1613-1620Informations de copyright
© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Bull Cancer. 2016 Sep;103(9):786-93
pubmed: 27206822
Support Care Cancer. 2022 Apr;30(4):3119-3129
pubmed: 34862578
J Hepatol. 2015 Jul;63(1):131-40
pubmed: 25724366
Nutr Clin Pract. 2017 Feb;32(1):30-39
pubmed: 28124947
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1053-1062
pubmed: 30269421
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Surgery. 2017 Mar;161(3):680-693
pubmed: 27712873
Sci Rep. 2018 Jul 27;8(1):11369
pubmed: 30054580
Ann Surg Oncol. 2018 Feb;25(2):439-448
pubmed: 29181681
Eur J Clin Nutr. 2018 Feb;72(2):288-296
pubmed: 29242526
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Scand J Gastroenterol. 2016 Jul;51(7):842-7
pubmed: 27001198
Ann Nutr Metab. 2017;71(3-4):145-149
pubmed: 28881342
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509
pubmed: 27891294
J Surg Oncol. 2019 Sep;120(3):473-482
pubmed: 31124178
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):527-528
pubmed: 28675689
Cancer Med. 2016 Apr;5(4):607-16
pubmed: 26814378
J Cachexia Sarcopenia Muscle. 2023 Aug;14(4):1613-1620
pubmed: 37203274
Int J Colorectal Dis. 2017 Jun;32(6):847-856
pubmed: 28190101
Clin Cancer Res. 2017 Feb 1;23(3):658-665
pubmed: 27489287
Thorac Cancer. 2018 Dec;9(12):1623-1630
pubmed: 30259689
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1429-1430
pubmed: 35218312
IEEE Trans Med Imaging. 2016 Feb;35(2):512-20
pubmed: 26415164
Am J Surg. 2018 Mar;215(3):503-506
pubmed: 29277239
BMC Geriatr. 2017 Aug 21;17(1):188
pubmed: 28826406
Oncologist. 2018 Jan;23(1):97-104
pubmed: 28935775
Radiology. 2019 Mar;290(3):669-679
pubmed: 30526356
Colorectal Dis. 2015 Jan;17(1):O20-6
pubmed: 25328119
J Cachexia Sarcopenia Muscle. 2020 Oct;11(5):1258-1269
pubmed: 32314543
Clin Nutr. 2014 Oct;33(5):737-48
pubmed: 24785098
Ann Surg. 2017 Nov;266(5):822-830
pubmed: 28796017
Am J Clin Nutr. 2015 Jul;102(1):58-65
pubmed: 26016860
Oncologist. 2016 Nov;21(11):1396-1409
pubmed: 27412391
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):630-638
pubmed: 28513088